Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2025-12-24 @ 11:34 PM
NCT ID:
NCT00006456
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed malignancy
* Extracranial recurrent or metastatic disease or primary tumor not predicted to be controlled with standard radiotherapy
* Incurable with any standard therapy
* No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or heart)
* Tumor visible by CT scan
PATIENT CHARACTERISTICS:
Age:
* Not specified
Performance status:
* Karnofsky 60-100%
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Bilirubin less than 2.0 times upper limit of normal (ULN)
* AST and ALT less than 5 times ULN
Renal:
* Creatinine less than 2.0 mg/dL
Pulmonary:
* FEV1 greater than 0.75 L
Other:
* No unsuitable size or geometric proportion that would preclude stereotactic immobilization
* Not pregnant or nursing
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* At least 14 days since prior anticancer biologic therapy and recovered
Chemotherapy:
* At least 14 days since prior anticancer chemotherapy and recovered
Endocrine therapy:
* At least 14 days since prior anticancer endocrine therapy and recovered
Radiotherapy:
* See Disease Characteristics
* At least 14 days since prior anticancer radiotherapy and recovered
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00006456
Study Brief:
Protocol Section:
NCT00006456